Obesity is a worsening pandemic with numerous related comorbid illnesses. Conservative management including lifestyle modification and medications have limited efficacy. In contradistinction, bariatric surgery is effective, however, with substantial cost and non-negligible morbidity and mortality. As such, a small percentage of eligible patients undergo surgery. Over the past decade, endoscopic bariatric and metabolic therapies have been introduced as a less invasive option for the treatment of obesity and its related comorbid illnesses. This article reviews major endoscopic bariatric and metabolic therapies, their surgical analogues, and proposed mechanisms of action. Clinical trial data for each device also are discussed.
O besity is an increasing pandemic. In 2012, more than one third of US adults were obese (body mass index [BMI] ! 30) and more than two thirds were overweight (BMI ! 25). 1 Similarly, there has been an increase in the prevalence of obesity-related comorbidities. In 2012, approximately 210 billion dollars were spent to treat obesity-related diseases in the United States, accounting for 21% of health care expenditures. 2 Sustained weight loss after lifestyle modification and pharmacotherapy is achieved in less than 5% of cases. 3 Bariatric surgery is more effective and durable. However, early and late complications remain as high as 30%, 4 and less than 1% of eligible patients undergo surgery. 5 Recently, endoscopic bariatric and metabolic therapies (EBMTs) have been developed to fill the gap between medical and surgical therapy. Similar to surgery, weight loss after EBMTs is described using percentage of total weight loss (%TWL). However, percentage of excess weight loss (%EWL) is still often used (Table 1) . Recently, the American Society for Gastrointestinal Endoscopy and the American Society for Metabolic and Bariatric Surgery defined acceptable thresholds of safety and efficacy for primary EBMTs. Specifically, these thresholds are based on a risk to benefit ratio with safety profile tolerance varying based on an efficacy rate, with a higher tolerance for serious adverse events for more efficacious procedures. Additionally, the new primary EBMT needs to be more efficacious than a sham or other appropriate control arm. 6 In this article, we review primary EBMTs, mechanisms of actions, and their surgical correlates. It is important to note that although some EBMTs are inspired by the surgeries that are no longer performed, this does not render the new endoscopic procedure invalid, particularly if the new procedure has enhanced features such as being reversible, repeatable, or less invasive. In addition, the exact mechanisms of the EBMTs and their surgical analogues may not be identical, and therefore the weight loss and metabolic outcomes may vary.
Mechanisms of Bariatric Surgery
Bariatric surgery historically was classified as restrictive (laparoscopic adjustable gastric band [LAGB] and laparoscopic sleeve gastrectomy [LSG] ), malabsorptive (biliopancreatic diversion [BPD] with duodenal switch [DS] ), or a combination of both (Rouxen-Y gastric bypass [RYGB] ). Restrictive procedures rely on decreasing the stomach's size and therefore reducing caloric intake, whereas malabsorptive procedures bypass a portion of the small bowel. Similarly, historically it was thought that weight loss was responsible for the improvement in metabolic comorbidities. However, there is now evidence that improvement in the metabolic profile is seen within days after surgery, before significant weight loss, with certain procedures. It similarly is now understood that the mechanisms of action for these procedures are more complicated than mere structural anatomic changes. Specifically, there appears to be a rapid alteration in gut hormones, which affect appetite, satiation, satiety, gut motility, and glucose and lipid homeostasis (Table 2 ). In addition, changes in bile acid concentration and gut flora are thought to play a role.
Gastric Hormones
Ghrelin. Ghrelin is secreted from X/A-like cells in the fundus. It is the only known orexigenic (appetite stimulant) gut hormone. Its levels are highest in the fasted state, and decrease postprandially. 7 It has been shown that ghrelin stimulates appetite and induces a positive energy balance that leads to weight gain. In addition, it also stimulates gastric and duodenal contraction and opposes the effects of other gastrointestinal peptides, such as cholecystokinin, that serve as satiety signals. 8 Bariatric surgeries have distinct effects on ghrelin secretion. LSG and RYGB are associated with decreased ghrelin levels, whereas LAGB is associated with increased ghrelin levels ( Table 2) . [9] [10] [11] [12] As such, the association between ghrelin levels and weight loss is varied and further study is needed.
Small Intestinal Hormones
Incretins. Incretins are a class of gut hormones that include glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). GIP is secreted postprandially from K cells in the duodenum and jejunum, and GLP-1 is secreted from L cells in the terminal ileum and proximal colon. It has been shown that an oral glucose load induces a greater release of insulin compared with intravenous glucose, a phenomenon known as the incretin effect. 13 In addition, GLP-1 suppresses glucagon secretion from pancreatic a cells, slows gastric emptying, reduces food intake, and crosses the blood-brain barrier to increase satiety. 14, 15 To date, it has been widely believed that GIP and GLP-1 are important factors that contribute to both weight loss and improvement in glycemic control after bariatric surgery. 16 Postprandial GIP secretion appears to decrease after RYGB, whereas postprandial GLP-1 levels appear to increase after RYGB, LAGB, and LSG (Table 2) . 9, [17] [18] [19] Peptide YY. Peptide YY (PYY) is an anorectic (appetite suppressant) gut hormone secreted postprandially from L cells in the distal ileum and proximal colon. It is associated with delayed gastric and intestinal transit, the so-called ileal break. In addition, PYY promotes satiety and Oxyntomodulin. Oxyntomodulin is co-secreted with GLP-1 from L cells in response to a meal. It inhibits gastric acid and pancreatic enzyme secretion, and delays gastric emptying. 20 In addition, it has been shown that oxyntomodulin can lead to decreased food intake, increased energy expenditure, and a reduction in body weight. Oxyntomodulin levels appear to increase after RYGB, although its role in inducing weight loss in other bariatric surgeries remains unclear.
Bile Acids
Bile acids, particularly secondary bile acids, have been shown to induce incretin secretion, which leads to increased insulin and decreased glucose levels. 21 RYGB bypasses the foregut and accelerates the intestinal transit time. This results in an increase in bile acids delivered to the distal gut and a higher ratio of secondary to primary bile acids. Increased bile acid concentrations have been shown to associate with higher GLP-1 and GIP levels, 21 which contribute to improvement in glycemic control. The role of bile acids in LAGB and LSG are less clear.
Gut Microbiota
It has been proposed that changes in intestinal flora may be associated with metabolic improvement after bariatric surgery. In obese subjects, the ratio of Firmicutes/Bacteroidaceae increases and bacterial diversity decreases. After RYGB, this trend reverses. 22 An increased prevalence of Bacteroidetes leads to increased conversion of primary to secondary bile acids via 7a-hydroxylase, leading to greater GIP and GLP-1 release. 23 
Gastric Endoscopic Procedures
EBMTs may be divided into gastric and small bowel interventions. Many of these were derived in part from surgical correlates and attempt to mimic their mechanisms. For gastric interventions, this is accomplished by stimulating gastric mechanical and chemical receptors, delaying gastric emptying, and modulating levels of gastric orexigenic hormones.
Analogues of Vertical Banded Gastroplasty
Vertical banded gastroplasty (VBG), or stomach stapling, was developed in 1980 by Mason 24 ( Figure 1A ). In this procedure, the upper stomach is stapled vertically to create a small pouch along the lesser curve. The bottom of the pouch is banded to create a 1-cm outlet into the remaining stomach. VBG restricts the amount of food that can be consumed and delays gastric emptying. Weight loss is approximately 16% AE 11% of baseline weight at 10 years. 25 However, only 10% of patients are able to maintain this weight loss. Because of a high failure rate and incidence of long-term complications, VBG is no longer performed. There have been 2 EBMTs that mimic the anatomy and mechanisms of VBG. These are the EndoCinch Endoluminal Vertical Gastroplasty (C.R. Bard, Inc, Murray Hill, NJ) and the TransOral GAstroplasty (Satiety Inc, Palo Alto, CA).
Endoluminal Vertical Gastroplasty (EVG). EVG is performed using the EndoCinch suturing device (C.R. Bard, Inc) and mimics the stapling portion of VBG without the banding portion ( Figure 1B) . Suturing was first applied to treat obesity in 2004, focusing on patients who had failed prior bariatric surgery. 26 In 2008, Fogel et al 27 used the same suturing device to perform EVG in 64 patients using a continuous running suture along the lesser curvature. No serious adverse events were reported and weight loss at 1 year was 58.1% AE 19.9% EWL.
TransOral GAstroplasty (TOGA). TOGA is an endoscopic stapling device that was introduced in 2008 ( Figure 1C ). 28 The device creates a stapled sleeve along the lesser curvature with a restricted outlet. Similar to VBG, TOGA is associated with decreased ghrelin and increased GLP-1 levels.
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A sham-controlled trial including 67 patients showed 52.2% AE 23.6% EWL (in patients with BMI < 40) and 41.3% AE 17.0% EWL (in those with BMI ! 40) after 1 year. Two cases of respiratory distress and an asymptomatic pneumoperitoneum from esophageal and gastric perforations that were treated conservatively, however, were reported. 30 Despite these results, the Food and Drug Administration (FDA) did not approve the system.
Analogues of Laparoscopic Adjustable Gastric Banding
LAGB is a primarily restrictive bariatric procedure in which an inflatable silicone band is placed around the upper part of the stomach with a subcutaneous port that allows adjustment ( Figure 1D ). It was introduced by Wilkinson in 1978, and later was placed laparoscopically for the first time by Belachew in 1993.
31,32 LAGB leads to delayed bolus transit to the infraband stomach, although it does not alter the overall gastric emptying time. 33 In addition, PYY levels increase after LAGB, which likely contribute to satiety and early satiation. There are no changes in GLP-1 levels and thus minimal direct glycemic effects. 9 Ghrelin levels increase after LAGB, likely as a secondary effect of weight loss. Weight loss after LAGB is approximately 47.1% AE 30.1% EWL at 13 years. However, up to 84.8% of patients experienced complications, 34 and LAGB recently has decreased in popularity.
The Transoral Endoscopic Restrictive Implant System (Barosense, Redwood City, CA) was developed as an endoscopic corollary to LAGB.
Transoral Endoscopic Restrictive Implant System (TERIS). The TERIS (Barosense) is an endoscopically implanted device introduced by Biertho et al 35 in 2009 ( Figure 1E ). It consists of a prosthetic diaphragm placed at the gastric cardia to create a small reservoir with a 10-mm orifice. Full-thickness plications are used to anchor the device. A pilot study including 13 patients reported 3 adverse events: 1 gastric perforation and 2 cases of pneumoperitoneum. At 3 months, a median EWL was 22.2%. 36 The device is no longer in clinical trials.
Analogues of Laparoscopic Gastric Plication
Laparoscopic gastric plication (LGP), or gastric imbrication was first performed by Kirk in 1968 (Figure 2A) . 37 During this procedure, the stomach is folded over and stitched to itself, resulting in a 75% reduction in gastric size. To date, LGP remains experimental. After LGP, ghrelin levels decrease, whereas GIP levels increase. 38 This likely is owing to infolding of the highly vascular fundus, which may result in decreased perfusion and ghrelin hyposecretion. Increased GIP levels may be owing to accelerated gastric emptying and/or contact with less well-digested chyme. In contrast to LSG, which is associated with an increase in postprandial GLP-1, no changes in GLP-1 have been observed after LGP. Previous studies have shown approximately 55% (range, 28%-100%) EWL at 5 years. However, up to one third of patients experienced weight regain at 12 years. There have been 3 endoscopic procedures that may mimic the effects of LGP. These are the RESTORe suturing system (Bard/Davol, Warwick, RI), Overstitch for Endoscopic Sleeve Gastroplasty (Apollo Endosurgery, Austin, TX), and the Incisionless Operating Platform for Primary Obesity Surgery Endolumenal (USGI Medical, San Clemente, CA).
RESTORe Suturing System: Transoral gastric volume Reduction as an Intervention for weight Management (TRIM) procedure. The RESTORe system is an updated version of the EndoCinch device (C.R. Bard, Inc) ( Figure 2B ). It is capable of deeper tissue acquisition and suture reloading in vivo. During this procedure, in addition to an anterior to posterior plication in EVG, the greater curvature also is incorporated, making this procedure an endoscopic sleeve gastroplasty (ESG) that mimics LGP. A pilot study (TRIM trial) including 18 patients showed 27.7% AE 21.9% EWL at 12 months. No significant adverse events were seen. Twelve-month endoscopy showed partial or complete release of plications in 13 of 18 patients. 40, 41 OverStitch for Endoscopic Sleeve Gastroplasty. The Apollo OverStitch (Apollo Endosurgery) is an endoscopic suturing device that applies full-thickness sutures in a variety of patterns ( Figure 2C ). The system attaches to a double-channel endoscope and uses a curved needle driver. In April 2012, Thompson and Hawes performed ESG procedures on patients in India. 42 This procedure was later modified to include medial interrupted reinforcing sutures based on the work of Abu Dayyeh et al, 43 which reported a series of 4 patients who underwent a version of ESG using 2 rows of interrupted stitches. Procedure development continued and the final study included 77 patients across international multicenters. In this series, patients experienced 17.4% AE 1.2% TWL at 1 year. 42 Subsequently, other investigators have reported similar results. [44] [45] [46] A multicenter trial (Primary Obesity Multicenter Incisionless Suturing Evaluation: the PROMISE trial) recently was completed. Twenty patients were included and lost 48.2% AE 9.9% EWL at 12 months. No serious adverse events were reported. 47 Similar to LGP, ESG appears to be associated with decreased ghrelin without significant changes in GLP-1 or PYY levels. ESG also has been shown to delay gastric emptying and increase satiation. 48 Incisionless Operating Platform for Primary Obesity Surgery Endolumenal. The incisionless operating platform (USGI Medical) has 4 working channels through which a 4.9-mm endoscope is passed, and specialized instruments are inserted to create full-thickness plications ( Figure 2D ). In 2013, Espinos et al 49 reported the use of this device to perform the Primary Obesity Surgery Endolumenal (POSE) procedure. 49 In this procedure, 8 to 9 plications are placed in the gastric fundus (via retroflexion) until the fundic apex is brought down to the level of the gastroesophageal junction. Subsequently, 3 to 4 plications are placed in the distal body. A pilot study including 45 patients showed no serious adverse events, and weight loss at 6 months was 49.4% AE 21.5% EWL. 49 A US pivotal sham-controlled study (ESSENTIAL trial) including 332 patients (221 POSE/111 sham) showed that the study arm lost 4.95% AE 7.04% EWL compared with 1.38% AE 5.58% EWL in the sham arm at 12 months. 50 POSE has been shown to delay gastric emptying and increase ghrelin (in contrast to LGP) and PYY levels. 51 In addition, post-POSE gastric emptying time and the degree of postprandial PYY increase have been shown to be an independent predictor of weight loss after POSE. 51 
Other Gastric Procedures
Intragastric balloons. The intragastric balloon (IGB) first was approved in the United States in 1985 with the Garren Edwards Gastric Bubble (American Edwards Laboratories, Mayaguez, PR). However, it was associated with multiple adverse events including gastric mucosal damage and small-bowel obstruction. A sham-controlled trial failed to show efficacy and the device was withdrawn from the market. 52 In the following decades, several IGBs have shown safety and efficacy, with broad adoption internationally. In the United States, the FDA approved 2 IGBs in 2015-the Orbera (Apollo Endosurgery) and the Reshape Duo balloons (Reshape, San Clemente, CA), and, more recently, the Obalon balloon (Obalon Therapeutics, Carlsbad, CA) in September 2016. 53 The Spatz Adjustable balloon (Spatz Medical, Great Neck, NY) currently is conducting its US pivotal trial, and the Elipse procedureless balloon (Allurion, Natick, MA) is planning on launching its pivotal trial next year.
Orbera Intragastric Balloon. The Orbera IGB (Apollo Endosurgery), formerly BioEnterics Intragastric Balloon, was developed in the early 1990s. Made of silicone, the balloon is placed in the fundus and filled with 450 to 700 mL of saline ( Figure 3A) . The balloon is implanted endoscopically and removed at 6 months. Dayyeh et al 54 showed that patients who received Orbera experienced a 47% delay in gastric emptying compared with baseline. In addition, rapid baseline gastric emptying and degree of slowing in gastric emptying after therapy were associated with %TWL at 6 months on univariate and multivariate analyses.
Orbera has been studied in multiple trials. A metaanalysis of 3698 patients showed 32.1% EWL at 6 months after balloon implantation (time of removal). 55 Reported adverse events included nausea, vomiting, bowel obstruction (0.8%), and gastric perforation (0.1%). Early device removal was required in 4.2% of patients. The long-term weight loss was 29.1% AE 60.3% EWL at 36 months after implantation. 56 In the US pivotal study (ORBERA trial), including 255 patients, TWL was 10.5% AE 6.6% at 6 months vs 4.7% AE 5.1% in the control group. 57 The difference in weight loss between the 2 groups was sustained at 12 months (6 months after removal).
ReShape Duo Intragastric Balloon. The ReShape IGB (Reshape) contains 2 silicone balloons attached to each other by a flexible tube ( Figure 3B ). It is inserted and retrieved endoscopically at 6 months. The ReShape Duo is filled with 900 mL of saline solution (450 mL to each balloon). Each balloon has independent channels to prevent deflation of the other balloon if one leaks.
A pilot study including 30 patients showed 31.8% EWL in the Reshape group compared with 18.3% in the control group. 58 In a US sham-controlled trial (REDUCE trial), including 326 patients, EWL was 25.1% in the Reshape arm compared with 11.3% in the sham arm. 59 Obalon Intragastric Balloon. The Obalon balloon (Obalon Therapeutics) is a 250-mL, gas-filled balloon that does not require endoscopic insertion, however, it is removed endoscopically ( Figure 3C ). For placement, the balloon is enclosed in a capsule that is attached to a slender tube. The capsule is swallowed under fluoroscopic visualization. A nitrogen-sulfur hexafluoride gas mixture then is used to inflate the balloon before removal of the tube. If the first balloon is tolerated, a second balloon can be swallowed at 4 weeks and a third balloon at 8 weeks. At 12 or 24 weeks, all balloons are removed endoscopically.
A pilot study including 17 patients showed that 98% of balloons were swallowed successfully. At 12 weeks, patients lost 36.2% (range, 0%-118%) EWL. 60 In a US pivotal trial (SMART trial), including 387 subjects (185 Obalon/181 sham), TWL was 6.81% AE 5.1% and 3.59% AE 5.0% in the treatment and control groups, respectively. One case of gastric ulcer was seen. 53 TransPyloric Shuttle. The TransPyloric Shuttle (BAROnova, Inc, Goleta, CA) consists of a spherical silicone bulb attached to a smaller silicone bulb by a flexible tether ( Figure 3D ). The device is delivered transorally via catheter and removed endoscopically. It remains in a transpyloric position with the smaller bulb entering the duodenum with peristalsis, and the larger bulb residing in the stomach intermittently occluding the pylorus. A pilot study including 20 patients reported 31.3% AE 15.7% and 50.0% AE 26.4% EWL at 3 and 6 months, respectively. The device was removed early in 2 patients owing to persistent gastric ulceration. 61 A US pivotal study (ENDOBESITY II) is in progress.
Full Sense Device. The Full Sense Device (Baker, Foote, Kemmeter, Walburn, LLC, Grand Rapids, MI) is a temporary reversible device that is deployed and removed endoscopically. It is a modified fully covered stent with an esophageal component and a gastric disk component ( Figure 3E ). It is designed to induce satiety and fullness in the absence of food by applying pressure on the distal esophagus and gastric cardia. The device currently is being studied in Europe.
Aspiration Therapy. The AspireAssist (Aspire Bariatrics, King of Prussia, PA) is a unique percutaneous gastrostomy tube that allows removal of a portion of an ingested meal approximately 20 to 30 minutes after consumption. Tube placement is similar to that of a standard percutaneous gastrostomy tube. Two weeks after insertion, the external portion of the tube is shortened and attached to a skin port ( Figure 3F ). An external device is connected to the skin port to perform aspiration after meals. A pilot study including 18 patients showed a 49.0% AE 7.7% EWL in the AspireAssist group compared with 14.9% AE 12.2% EWL in the control group. 62 In a US pivotal study (Pivotal Aspiration Therapy with Adjusted Lifestyle: the PATHWAY trial), including 171 patients, the EWL in the AspireAssist arm was 31.5% AE 26.7% compared with 9.8% AE 15.5% in the control arm at 1 year. Serious adverse events were reported in 3.6% of patients in the treatment arm. No evidence of increased food intake or development of abnormal eating behaviors was found. 63 In June 2016, the device was approved by the FDA for long-term implantation.
Botulinum Toxin Injection. Botulinum toxin A (BTX-A) is a selective acetylcholine inhibitor that blocks smooth and striated muscle contraction. Because vagus-mediated antral contractions are important for food propulsion into the duodenum, it has been hypothesized that antral BTX-A injection may lead to weight loss by delaying gastric emptying and inducing satiety. In 2006, Albani et al 64 performed proof-of-concept work that prompted subsequent studies with mixed results. In a meta-analysis including 8 studies, regression showed that wide area injections including the fundus or body rather than the antrum alone and multiple injections (>10) were associated with weight loss. 65 However, BTX-A injections remain controversial and more studies are needed.
Small-Bowel Endoscopic Procedures
The proximal small bowel plays an important role in glucose homeostasis. Also known as the incretin effect, oral glucose intake leads to amplification of insulin secretion compared with intravenous infusion. This effect is understood to be owing to gut hormones as detailed earlier. In addition to their effect on glucose homeostasis, these gut hormones also affect satiety and gastrointestinal motility. Therefore, small-bowel EBMTs may contribute to weight loss as well as diabetes improvement.
Analogues of Roux-en-Y Gastric Bypass
RYGB was developed by Mason and Ito 66 in 1967 ( Figure 4A ). Since then, the procedure has undergone several technical modifications and has been a preferred bariatric procedure for the past several decades. During RYGB, the stomach is divided into a 20-to 30-mL pouch and a larger remnant stomach. The pouch is connected to the jejunal Roux limb, bypassing the gastric remnant, duodenum, and proximal jejunum. RYGB patients experienced 27% AE 12% TWL and had a decreased mortality rate compared with control subjects at 15 years. 25 In addition, RYGB patients had resolution of diabetes (hemoglobin A1c [HbA1c] level of 6% or less) more commonly than those who received medical treatment (38% vs 5%, respectively). 67 After RYGB, ghrelin levels decrease, whereas GLP-1, PYY, oxyntomodulin, and cholecystokinin levels increase. 9, 11 This postprandial spike in incretins is thought to be due to early delivery of bile and nutrients to the distal small bowel, as suggested by hindgut theory. Furthermore, foregut theory hypothesizes that a substance is released from the duodenum that contributes to insulin resistance, and that in bypassing this segment of bowel the release of the substance is suppressed, leading to improvement in insulin resistance. It is thought that RYGB likely exploits these and several other mechanisms.
There have been 3 endoscopic devices that attempted to mimic elements of RYGB. These are the Endoluminal Bypass (ValenTx, Maple Grove, MN), EndoBarrier (GI Dynamics, Inc, Lexington, MA), and Duodenal Mucosal Resurfacing (Fractyl Laboratories, Lexington, MA).
Endoluminal bypass. The Endoluminal Bypass (ValenTx) is a 120-cm sleeve secured at the gastroesophageal junction to create an endoluminal gastroduodenojejunal bypass that mimics the anatomic changes of RYGB ( Figure 4B ). The sleeve is placed and removed endoscopically. In a pilot study, 12 patients had the device placed, with 2 requiring early explanation as a result of intolerance. Of the remaining 10 patients, 6 had fully attached and functional sleeves at the 1-year follow-up evaluation, and 4 had partial cuff detachment seen at follow-up endoscopy. Weight loss at 1 year was 54% EWL among the 6 patients with intact sleeves. Comorbidities including diabetes, hypertension, and hyperlipidemia all improved. 68 The company currently is planning a US trial.
EndoBarrier. The EndoBarrier (GI Dynamics, Inc), also known as duodenal-jejunal bypass liner (DJBL), is a 60-cm fluoropolymer liner that is anchored at the duodenal bulb and terminates at the proximal jejunum ( Figure 4C ). It is inserted endoscopically with fluoroscopic guidance. Ingested nutrients pass from the stomach into the liner directly into the jejunum without contacting the duodenum. Pancreatic enzymes and bile pass into the gastrointestinal tract, flowing down between the liner and the intestinal wall, mixing with ingested nutrients at the jejunum. A pilot study including 12 patients showed 23.6% (range, 12.5%-41.5%) EWL in 10 of the 12 patients. Two of the 12 patients underwent early explantation. 69 A recent meta-analysis including 151 subjects from 4 randomized controlled studies showed that DJBL implantation led to an additional 12.6% EWL compared with control interventions. In addition, the study showed a significant effect of DJBL on fasting plasma glucose level compared with diet modification. More patients in the DJBL group were able to discontinue or reduce the dose of antidiabetic medication when compared with the control group. 70 A US pivotal trial (the ENDO trial) met efficacy end points with 60% of the patients losing 5% or more TWL and 34.8% achieving HbA1c level of 7% or less (compared with 20% and 9.8% in the sham arm, respectively). The trial was stopped early by the company owing to a 3.5% hepatic abscess rate. 71 All cases were managed conservatively and did not require intensive care unit stay, however, this was outside the predetermined serious adverse event rate. Further studies are under way.
Duodenal Mucosal Resurfacing. Duodenal mucosal resurfacing (DMR) (Fractyl), or the Revita procedure, is an endoscopic procedure that applies radiofrequency to thermally ablate the superficial duodenal mucosa ( Figure 4D ). It is hypothesized that mucosal remodeling may reset duodenal enteroendocrine cells that have become diseased. As a result, the procedure may restore signaling and amplify the incretin effect to improve diabetes mellitus. A study of 39 patients with poorly controlled diabetes mellitus who underwent long-segment DMR (>9 cm; n ¼ 28) or short-segment DMR (<6 cm; n ¼ 11) was performed. At 6 months, HbA1c level decreased from 9.5% to 8.3% for the entire cohort. More glycemic effect was seen in the long-segment cohort compared with the shortsegment cohort, suggesting a dose-dependent treatment effect from DMR. Three patients experienced duodenal stenosis and were treated successfully with balloon dilation. 72 Currently, a multicenter study is being conducted in Europe and a US pivotal trial is planned.
Analogue of Variant Biliopancreatic Diversion
With a Duodenal Switch BPD was described by Scopinaro et al 73 in 1979 . It consists of a horizontal gastrectomy, which leaves an upper stomach that is connected to the distal 250 cm of small intestine. Bile and pancreatic enzymes travel down the excluded small intestine (including the duodenum, jejunum, and proximal ileum) and mix with the nutrients in the common limb. BPD with a duodenal switch is a variant of BPD in which sleeve gastrectomy (SG) is performed instead of horizontal gastrectomy. The small intestine is divided at the duodenum and a duodeno-ileal anastomosis is performed (duodenal switch [DS] ). These procedures are performed in small numbers in the United States.
A variant of these procedures involving just the DS with no SG (DS-SG) has been described in clinical research studies in Laval, Canada ( Figure 4E) . 74 Patients who underwent DS-SG alone were compared with those who received SG alone, and the combination. At 1 year, the DS-SG group experienced 39% AE 13% EWL compared with 47% AE 19% EWL in the SG group. However, SG patients had significant weight regain and experienced only 12% AE 35% EWL compared with 45% AE 19% EWL in the DS-SG group at 5 years. The HbA1c level decreased by 10% and 19% in the SG and DS-SG groups, respectively. These data suggest a more durable weight loss effect for distal smallbowel anastomosis as well as better glycemic control.
A surgical procedure that is structurally different but may be mechanistically similar to BPD is the ileal transposition. Described by De Paula et al 75 in 1999, the procedure involves resecting a 10-to 20-cm portion of the distal ileum and then transposing it into the proximal jejunum. This results in early delivery of food chyme to the ileum, while the total length of the small bowel remains unaffected. Compared with a sham procedure, ileal transposition has been shown to lead to greater weight loss and reduced food intake in rats. 76 In addition, GLP-1 and PYY increased after ileal transposition. 76, 77 The Incisionless Magnetic Anastomotic System (IMAS) (GI Windows, West Bridgewater, MA) is used to create an enteral diversion that is functionally similar to DS-SG and mechanistically similar to ileal transposition.
Incisionless Magnetic Anastomotic System. The IMAS (GI Windows) creates an anastomosis via incisionless magnetic compression. This technology has many applications, including a bariatric dual-path enteral diversion procedure. During this procedure, enteroscopy and colonoscopy are performed simultaneously. The IMAS selfassembling magnets are deployed from the working channel of each endoscope, forming magnetic octagons in the jejunum and ileum. After a week, a compression anastomosis is completely formed and the coupled magnets spontaneously pass ( Figure 4F ). A study including 10 patients showed 14.6% (range, 0.3%-41.8%) TWL at 1 year. The HbA1c level decreased from 6.6% AE 1.8% to 5.4% AE 0.5%. 78 The postprandial GLP-1 level increased at 2 months, however, longer-term results are needed to draw further conclusions.
Other Small-Bowel Procedures
SatiSphere. SatiSphere (Endosphere, Columbus, OH) consists of a nitinol memory wire with 2 pigtals at each end, and several polyethylene terephthalate spheres along the wire ( Figure 3G ). It is implanted endoscopically into the duodenum and takes a C-shape configuration. In a randomized pilot study, including 31 patients, the study arm experienced 18.4% EWL compared with 4.4% EWL in the control arm. In addition, the device was associated with delayed glucose absorption, insulin secretion, and altered GLP-1 kinetics. 79 Device migration occurred in 10 of 21 study arm patients, with 2 necessitating emergent surgery. The European study currently is ongoing.
Conclusions
EBMTs have the potential to transform the treatment of obesity, which remains a growing pandemic. In this article, primary EBMTs are reviewed as a more effective option than lifestyle modification and medical therapy, with less invasiveness and greater accessibility than bariatric surgery. In addition to primary intervention, EBMTs also have various applications including preventive therapy, bridging therapy, cosmetic therapy, and revision of bariatric surgery. Understanding the mechanisms of actions of each EBMT, and studying their surgical correlates that have a longer track record, may provide us with information to better personalize therapy. In addition, combining devices with different mechanisms of action, and using drug-device combinations, may enhance the effectiveness of these procedures. Furthermore, because obesity is a chronic disease, these less-invasive and reversible options may allow sequential therapy to manage this condition more optimally in the long term.
